Zaleplon is a Sleep-Onset Medication
Zaleplon is specifically indicated for sleep-onset insomnia, not sleep maintenance. This is due to its ultra-short half-life of approximately 1 hour, which makes it effective at reducing the time to fall asleep but provides little benefit for staying asleep throughout the night.
Pharmacokinetic Basis
Zaleplon's classification as a sleep-onset agent is directly related to its pharmacokinetic profile 1, 2:
- Half-life: Approximately 1 hour 3
- Time to peak concentration: Approximately 1 hour 3
- Rapid elimination: Cleared from the body within 4 hours 4
This ultra-short duration of action means zaleplon is rapidly absorbed, reaches peak levels quickly, and is eliminated before the middle and later portions of the night.
Clinical Evidence and Guideline Recommendations
The 2017 American Academy of Sleep Medicine (AASM) Clinical Practice Guideline explicitly states: "We suggest that clinicians use zaleplon as a treatment for sleep onset insomnia (versus no treatment) in adults" 2. This recommendation is based on trials using 10 mg doses.
The 2008 AASM guideline similarly notes that "zaleplon and ramelteon have very short half-lives and consequently are likely to reduce sleep latency but have little effect on waking after sleep onset (WASO)" 1.
Clinical Trial Data
Studies consistently demonstrate zaleplon's selective effect on sleep initiation 2:
- Sleep latency: Zaleplon 10 mg reduced objective sleep latency by approximately 9.5 minutes compared to placebo, meeting criteria for clinical significance 2
- Total sleep time: No consistent significant improvement compared to placebo 2
- Wake after sleep onset (WASO): Not significantly different from placebo 2
- Sleep maintenance: Generally not improved 5, 6
The FDA label confirms that zaleplon "has been shown to decrease the time to sleep onset" but "has not been shown to increase total sleep time or decrease the number of awakenings" 3.
Practical Clinical Implications
Advantages of Sleep-Onset Specificity
- No residual sedation: Unlike longer-acting agents, zaleplon produces no next-day impairment as early as 4 hours after dosing 4
- Flexible dosing: Can be taken at bedtime or even during the night if at least 4 hours of sleep time remains 4
- Minimal withdrawal effects: No rebound insomnia observed with 5-10 mg doses 2
When NOT to Use Zaleplon
Zaleplon is inappropriate for patients whose primary complaint is:
- Frequent nocturnal awakenings
- Early morning awakening
- Inability to maintain sleep throughout the night
For these sleep maintenance problems, longer-acting agents like eszopiclone, temazepam, zolpidem extended-release, or doxepin would be more appropriate 1, 2.
Comparison with Other Agents
The guidelines clearly distinguish zaleplon from sleep maintenance medications 1:
- Sleep maintenance agents: Eszopiclone, temazepam, doxepin, suvorexant - these have longer half-lives and improve WASO
- Sleep onset agents: Zaleplon, ramelteon, triazolam - these have short half-lives and primarily reduce sleep latency
Dosing Considerations
- Standard dose: 10 mg at bedtime 2
- Elderly or debilitated patients: 5 mg 1
- Hepatic impairment: 5 mg (contraindicated in severe hepatic impairment) 1, 3
Common Pitfall to Avoid
Do not prescribe zaleplon expecting improvement in sleep maintenance or total sleep duration. Patients with middle-of-the-night or early morning awakening as their primary complaint will likely be dissatisfied with zaleplon's effects. Match the medication's pharmacokinetic profile to the patient's specific insomnia phenotype: sleep-onset difficulty = zaleplon; sleep maintenance difficulty = longer-acting alternatives.